With the exception of intrathecal chemotherapy (methotrexate strongly preferred; cytarabine is permissible) administered at the time of the required diagnostic lumbar puncture to establish baseline CNS status, patient has not received prior relapse-directed therapy (i.e., this protocol is intended as the INITIAL treatment of first relapse)
Treatment with hydroxyurea, corticosteroids (any route) and intrathecal cytarabine prior to beginning protocol directed therapy is allowed; however, it should be noted that lumbar puncture and intrathecal therapy at initial diagnosis of APL is not recommended
Central nervous system (CNS) status must be determined based on a sample obtained prior to the administration of any systemic or intrathecal chemotherapy, with the exception of steroid pretreatment
With the exception of steroid pretreatment or the administration of intrathecal methotrexate or intrathecal cytarabine, receipt of any other prior cytotoxic chemotherapy for either the current diagnosis of B-ALL or any cancer diagnosed prior to the initiation of protocol therapy on AALLP
Intrathecal chemotherapy prior to enrollment is allowed for the current diagnosis of ALCL as long as adequate cerebrospinal fluid (CSF) is obtained prior to administration of the intrathecal chemotherapy and subsequently demonstrated to be negative for ALCL
No prior therapy for ALL except for limited treatment (=<  days) with corticosteroids or hydroxyurea and a single dose of intrathecal cytarabine; however, patients who are being treated with chronic steroids for other reasons (for example, to treat asthma, autoimmune disorders, lupus, etc.) are eligible
Single-dose intrathecal cytarabine is allowed prior to registration or prior to initiation of systematic therapy for patient convenience; systemic chemotherapy must begin within  hours of this intrathecal therapy
Participants who have had systemic chemotherapy or radiotherapy within  days prior to entering the study, except for hydroxyurea or -mercaptopurine (MP) as noted; empiric intrathecal chemotherapy during a diagnostic lumbar pucture is allowed, as long as central nervous system (CNS) disease is not suspected
Central nervous system (CNS) involvement with disease refractory to intrathecal chemotherapy
Participant must be previously untreated, (no more than  hours of steroids, one intrathecal chemotherapy treatment, and/or emergency radiation)
PARTICIPANTS FROM COLLABORATING SITES PARTICIPATING IN BIOLOGICAL OBJECTIVES ONLY: Participant must be previously untreated, (no more than  hours of steroids, one intrathecal chemotherapy treatment, and/or emergency radiation)
Prior treatment with any methotrexate containing systemic regimen within  year (excluding intrathecal methotrexate)
Current concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in the protocol; consolidative radiation therapy (RT) after completion of planned course and/or concurrent intrathecal chemotherapy for central nervous system (CNS) disease prophylaxis is permissible
Patients with central nervous system involvement by ALL are eligible and may receive concomitant treatment with radiation therapy and/or intrathecal chemotherapy in accordance with standard medical practice; for patients with central nervous system (CNS) disease, dexamethasone may be temporarily administered instead of prednisone to reduce CNS pressure, at the discretion of the treating physician and after discussion with the Memorial Sloan-Kettering (MSK) principal investigator (PI); once dexamethasone is no longer needed, prednisone should be given as per protocol for  days
Limited prior therapy, including hydroxyurea for  hours or less, systemic glucocorticoids for one week or less, one dose of vincristine, and one dose of intrathecal chemotherapy
Central nervous system involvement with lymphoma at any time in the patients history; intrathecal prophylaxis during induction is allowed as long as active disease has not been identified
Patients with central nervous system (CNS) involvement refractory to intrathecal chemotherapy and/or standard cranial-spinal radiation
Emergent radiation therapy, one dose of intrathecal chemotherapy, and up to  days of steroids for treatment of relapse are permitted before start of treatment in participants who relapse after completion of frontline therapy
TREATMENT WITH SJCAR: Receiving intrathecal chemotherapy in the  days prior to CAR T-cell infusion
Concurrent chemotherapy or targeted anti-cancer agents, other than intrathecal therapy
Patients must not be receiving any chemotherapy agents (except hydroxyurea); intrathecal methotrexate and intrathecal cytarabine are permissible
The use of other chemotherapeutic agents or anti-leukemic agents is not permitted during study with the following exceptions () intrathecal chemotherapy for prophylactic use or for controlled central nervous system (CNS) leukemia. () use of hydroxyurea and/or one dose of cytarabine (up to  g/m^) or hydroxyurea for patients with rapidly proliferative disease is allowed before the start of study therapy and for the first four weeks on therapy.
Radiotherapy or cancer chemotherapy (except for intrathecal prophylaxis and/or low-dose maintenance therapy such as vinca alkaloids, mercaptopurine, methotrexate, steroids) or any investigational drug within  weeks before study entry
Central nervous system (CNS) leukemia (including leukemia detectable in the cerebrospinal fluid and/or solid chloromas) refractory to intrathecal chemotherapy and/or craniospinal radiation
CNS involvement with disease refractory to intrathecal chemotherapy
Radiotherapy and cancer chemotherapy (except for intrathecal chemotherapy, hydroxyurea, and cytarabine. Cytarabine and hydroxyurea are allowed to be used emergently in case of leukocytosis) or any investigational drug within  weeks before study entry
Known, active leptomeningeal leukemia requiring intrathecal therapy. NOTE: Patients with a history of CNS disease may be allowed to participate based on at least  consecutive documented, negative spinal fluid assessment prior to Screening
Patients with active central nervous system leukemia or requiring maintenance intrathecal chemotherapy
Known, active leptomeningeal leukemia requiring intrathecal therapy. NOTE: Patients with a history of CNS disease may be allowed to participate based on at least  documented, negative spinal fluid assessment within  days prior to Screening
Active uncontrolled central nervous system (CNS) leukemia; NOTE: positive (cyto)pathology is allowed and patient can receive intrathecal chemotherapy
Subjects must not be receiving any chemotherapy agents (except hydroxyurea)\r\n* Intrathecal methotrexate and cytarabine are permissible
Radiotherapy and cancer chemotherapy (except for intrathecal prophylaxis and/or low-dose maintenance therapy such as vinca alkaloids, mercaptopurine, methotrexate, steroids) or any investigational drug within  weeks before study entry
Patients must not be currently receiving any chemotherapy agents (except hydroxyurea)\r\n* Intrathecal cytarabine (ARA-C) and intrathecal methotrexate are permissible (as they are not systemic and only isolated to the central nervous system)\r\n* Patients cannot have received more than  prior lines of therapy for their hematologic malignancy; patient may have previously had azacitidine or decitabine and still be eligible
Central nervous system (CNS) tumor refractory to intrathecal chemotherapy and/or cranio-spinal radiation
Participants with known central nervous system (CNS) involvement with leukemia or who are receiving intrathecal chemotherapy that is either prophylactic or therapeutic; history of CNS involvement that has been completely treated (no longer receiving intrathecal chemotherapy) will be allowed
Central nervous system (CNS) involvement with disease refractory to intrathecal chemotherapy
Central nervous system (CNS) leukemic involvement not clearing with intrathecal chemotherapy and/or cranial radiation prior to initiation of conditioning (day -)
No prior therapy for this malignancy except for one dose of intrathecal therapy and the use of hydroxyurea or low-dose cytarabine (- mg/m^ per day for one week or less for hyperleukocytosis), and
Patients who are currently receiving or plan to receive other anti-cancer agents (except hydroxyurea, which may be continued until  hours prior to start of protocol therapy and intrathecal chemotherapy)
Ongoing treatment with any other cancer therapy or investigational agent, with the exception of intrathecal (IT) chemotherapy for leukemia, when indicated
Patients must not have received any cytotoxic chemotherapy for either the current diagnosis of T-ALL, T-L-Ly or for any cancer diagnosis prior to the initiation of protocol therapy on AALL, with the exception of:\r\n* Steroid pretreatment: prednisone or methylprednisolone for =<  hours ( days) in the  days prior to initiating induction chemotherapy or for =<  hours ( days) in the  days prior to initiating induction chemotherapy; prior exposure to ANY steroids that occurred >  days before the initiation of protocol therapy does not affect eligibility; the dose of prednisone or methylprednisolone does not affect eligibility\r\n* Intrathecal cytarabine (the CNS status must be determined based on a sample obtained prior to administration of any systemic or intrathecal chemotherapy, except for steroid pretreatment) system chemotherapy must begin with  hours of this IT therapy; or\r\n*  cGy of chest irradiation, if medically necessary\r\n** Pre-treatment with dexamethasone in the  days prior to initiation of protocol therapy is not allowed with the exception of a single dose of dexamethasone use during sedation to prevent or treat airway edema; inhalation steroids and topical steroids are not considered pretreatment
Subjects must not be receiving any chemotherapy agents (except hydroxyurea); intrathecal methotrexate and cytarabine are permissible
Intrathecal cytotoxic therapy:\r\n* No waiting period is required for patients having received intrathecal cytarabine, methotrexate, and/or hydrocortisone\r\n* At least  days must have elapsed since receiving liposomal cytarabine (DepoCyte) by intrathecal injection
With central nervous system (CNS) leukemic involvement not clearing with intrathecal chemotherapy, cranial irradiation or both prior to initiating conditioning (day -)
Patients with central nervous system (CNS) involvement refractory to intrathecal chemotherapy
CNS prophylaxis treatment must be stopped >  week prior to CTL infusion (e.g. intrathecal methotrexate) f. Radiotherapy:
CNS disease prophylaxis must be stopped >  week prior to CTL infusion (e.g. intrathecal methotrexate)
CNS disease prophylaxis: CNS prophylaxis treatment must be stopped >  week prior to CTL infusion (e.g. intrathecal methotrexate)
Active AML involvement of the central nervous system (CNS) with disease refractory to intrathecal chemotherapy
Patients with central nervous system  (CNS) leukemia\r\n* CNS status must be known prior to enrollment; (Note: the CNS status must be determined based on a sample obtained prior to administration of any systemic or intrathecal chemotherapy, except for steroid pretreatment); B-LLy patients with CNS disease are not eligible for this protocol or the COG HR ALL protocol; it is recommended that intrathecal cytarabine be administered at the time of the diagnostic lumbar puncture; this is usually done at the time of the diagnostic bone marrow or venous line placement to avoid a second lumbar puncture; this is allowed prior to registration; systemic chemotherapy must begin within  hours of the first dose of intrathecal therapy
Symptomatic or untreated central nervous system (CNS) leukemia. Subjects are permitted to enroll if previously treated for CNS disease, free of symptoms at the time of screening, and have not required intrathecal chemotherapy at least  month prior to study Day .
Active uncontrolled central nervous system (CNS) leukemia; NOTE: positive (cyto)pathology is allowed and patient can receive intrathecal chemotherapy
Patients with known active central nervous system leukemia should be excluded from this clinical trial; patient receiving intrathecal chemotherapy prophylaxis should not receive pomalidomide for >=  days after administration
Patients with central nervous system (CNS) involvement refractory to intrathecal chemotherapy and/or standard cranial-spinal radiation
Subjects must not have received any chemotherapeutic agents for the AML (except hydroxyurea); intrathecal cytarabine (ARA-C) and intrathecal methotrexate are permissible
Patients who have had chemotherapy or radiotherapy within  weeks except for intrathecal chemotherapy (i.e., methotrexate, cytarabine, or thiotepa)
No prior therapy for recurrent ALL is allowed prior to study entry with the exception of intrathecal (IT) chemotherapy; participants who have relapsed while receiving up-front therapy are eligible, but must have recovered from adverse effects from any previously administered agents
Patients with central nervous system involvement by APL are eligible and may receive concomitant treatment with radiation therapy and/or intrathecal chemotherapy in accordance with standard medical practice
Central nervous system (CNS) involvement with disease refractory to intrathecal chemotherapy
Central nervous system (CNS) involvement with disease refractory to intrathecal chemotherapy
No prior therapy for this malignancy except for one dose of intrathecal therapy and the use of hydroxyurea or low-dose cytarabine (- mg/m^ per day for one week or less) for hyperleukocytosis
Patients with relapse also detected in the central nervous system (CNS) may be treated on this protocol; however, if intrathecal chemotherapy is being administered, T cells should not be administered until at least  hours thereafter
Central nervous system (CNS) involvement with disease refractory to intrathecal chemotherapy and/or standard cranial-spinal radiotherapy
Central nervous system (CNS) involvement with disease refractory to intrathecal chemotherapy
Patients may be enrolled on study regardless of the timing of prior Intrathecal therapy; however, they MAY NOT BEGIN TREATMENT ON THIS PROTOCOL UNTIL A MINIMUM OF  DAYS HAS ELAPSED SINCE PRIOR INTRATHECAL THERAPY.
Intrathecal therapy with cytarabine is allowed prior to registration for patient convenience; systemic chemotherapy must begin within  hours of the first intrathecal treatment
Patients with central nervous system (CNS) metastasis. Intrathecal chemotherapy is allowed for patients who require CNS prophylaxis or therapy.
No limitations on prior systemic or intrathecal therapies
Concurrent chemotherapy, or targeted anti-cancer agents, other than hydroxyurea, low-dose cytarabine, intrathecal therapy and/or low dose maintenance therapy such as vincristine, mercaptopurine, methotrexate or glucocorticoids
Use of investigational agents within  days or any anticancer therapy within  weeks before study entry with the exception of hydroxyurea, low dose cytarabine and intrathecal chemotherapy
Inability to receive lumbar intrathecal injection because of other factors
Prophylactic intrathecal chemotherapy;
Prior AML therapy, with the exception of intrathecal chemotherapy or emergent radiation for myeloid sarcoma.
